Physician profile
Ross E Weller
NPI 1952834269
$7,209.02
in general payments reported to CMS, 2019-2025
18 companies · $275 in 2025
The $275 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $5,197 · 2024: $1,737 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,022 · Travel and Lodging: $1,163 · Food and Beverage: $1,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,022.49 |
| Travel and Lodging | $1,162.79 |
| Food and Beverage | $1,023.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,544.10 | 2023-2024 | Davinci Xi, Da Vinci Surgical System, Da Vinci Sp |
| Integra Lifesciences Corporation | $168.32 | 2023-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Tela Bio, INC. | $101.82 | 2024 | Ovitex 2s |
| Lilly USA, LLC | $63.14 | 2024-2025 | Omvoh |
| Smith+Nephew, INC. | $39.08 | 2025 | Grafix |
| Kerecis Limited | $36.43 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Acera Surgical, INC. | $31.79 | 2025 | Restrata Wound Matrix |
| Humacyte Global, INC. | $26.18 | 2025 | Symvess |
| Solventum Corporation | $22.97 | 2025 | Prevena |
| Celltrion USA INC. | $22.49 | 2024 | Zymfentra |
| Orphalan INC | $21.76 | 2024 | Cuvrior |
| Janssen Biotech, INC. | $21.08 | 2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.58 | 2023 | Jardiance |
| Cumberland Pharmaceuticals, INC. | $18.95 | 2025 | Caldolor |
| Innovation Technologies INC | $18.58 | 2025 | Irrisept |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $17.53 | 2024 | Voquezna |
| Braintree Laboratories, INC. | $17.13 | 2024 | Sutab, Suflave |
| Organogenesis INC. | $17.09 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Weller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.